BREMEN Eye Drops Versus Combigan for Open-angle Glaucoma or Intraocular Hypertension

Inclusion Criteria:

• Signed Consent;
• Participants with diagnosis of open-angle glaucoma or hypertension ocular, who needstreatment with drugs association to control the intraocular pressure;
• Participants who have 20/80 visual acuity or more, in both eyes;

Exclusion Criteria:

• Participants with any clinical significant disease that, after evaluation of theinvestigator, can´t participate in the study;
• Participants with active eye disease, which in the investigator opinion may interferein the results of this clinical trial;
• Participants presenting previous diagnosis of non-operated cataract, high myopia, highastigmatism, pseudoexfoliation and corneal deformities;
• Participants who had significant visual loss in the last year;
• Treatment-naive participants for open-angle glaucoma or ocular hypertension;
• Participants nonresponders to previous triple combination drug therapy, used inconcomitance;
• Participants with previous ocular or intraocular surgery within six months prior toenrollment in the clinical trial;
• Participants with history of hypersensitivity to any formula compounds;
• Participants presenting contraindications to use of beta-adrenergic antagonists;
• Participants diagnosed with uncontrolled cardiovascular disease;
• Participants with severe renal insufficiency or hyperchloremic acidosis;
• Participants in therapy with monoamine oxidase inhibitors (MAOIs);
• Participants who were in use of drugs that can interfere in the evaluation;
• Pregnancy or risk of pregnancy and lactating patients;
• Alcoholism or illicit drug abuse in the last two years;
• Participation in clinical trial in the year prior to this study.